Bellicum Pharmaceuticals BLCM Stock
Bellicum Pharmaceuticals Price Chart
Bellicum Pharmaceuticals BLCM Financial and Trading Overview
| Bellicum Pharmaceuticals stock price | 0.07 USD |
| Previous Close | 0.4 USD |
| Open | 0.4 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 0.34 - 0.4 USD |
| 52 Week Range | 0.15 - 1.55 USD |
| Volume | 18.77K USD |
| Avg. Volume | 3.05M USD |
| Market Cap | 3.56M USD |
| Beta (5Y Monthly) | 1.512676 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5 USD |
BLCM Valuation Measures
| Enterprise Value | 10.96M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.39010417 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.3583317 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 7.268 |
| Enterprise Value/EBITDA | -0.369 |
Trading Information
Bellicum Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.512676 |
| 52-Week Change | -64.22% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.55 USD |
| 52 Week Low | 0.15 USD |
| 50-Day Moving Average | 0.51 USD |
| 200-Day Moving Average | 0.88 USD |
BLCM Share Statistics
| Avg. Volume (3 month) | 3.05M USD |
| Avg. Daily Volume (10-Days) | 234.98K USD |
| Shares Outstanding | 9.5M |
| Float | 8.42M |
| Short Ratio | 0.17 |
| % Held by Insiders | 4.19% |
| % Held by Institutions | 29.30% |
| Shares Short | 1.44M |
| Short % of Float | 17.08% |
| Short % of Shares Outstanding | 15.15% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1968.63% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -61.14% |
| Return on Equity (ttm) | -106.13% |
Income Statement
| Revenue (ttm) | 1.51M USD |
| Revenue Per Share (ttm) | 0.05 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -29678000 USD |
| Net Income Avi to Common (ttm) | -25477000 USD |
| Diluted EPS (ttm) | -0.84 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 15.4M USD |
| Total Cash Per Share (mrq) | 1.62 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 3.655 |
| Book Value Per Share (mrq) | -1.108 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -25836000 USD |
| Levered Free Cash Flow (ttm) | -17431376 USD |
Profile of Bellicum Pharmaceuticals
| Country | United States |
| State | TX |
| City | Houston |
| Address | 3730 Kirby Drive |
| ZIP | 77098 |
| Phone | 281 454 3424 |
| Website | https://www.bellicum.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 13 |
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
Q&A For Bellicum Pharmaceuticals Stock
What is a current BLCM stock price?
Bellicum Pharmaceuticals BLCM stock price today per share is 0.07 USD.
How to purchase Bellicum Pharmaceuticals stock?
You can buy BLCM shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Bellicum Pharmaceuticals?
The stock symbol or ticker of Bellicum Pharmaceuticals is BLCM.
Which industry does the Bellicum Pharmaceuticals company belong to?
The Bellicum Pharmaceuticals industry is Biotechnology.
How many shares does Bellicum Pharmaceuticals have in circulation?
The max supply of Bellicum Pharmaceuticals shares is 10.41M.
What is Bellicum Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Bellicum Pharmaceuticals PE Ratio is 0.00000000 now.
What was Bellicum Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Bellicum Pharmaceuticals EPS is 0 USD over the trailing 12 months.
Which sector does the Bellicum Pharmaceuticals company belong to?
The Bellicum Pharmaceuticals sector is Healthcare.
Bellicum Pharmaceuticals BLCM included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16920.58 USD — |
-0.58
|
6.33B USD — | 16873.97 USD — | 16989.6 USD — | — - | 6.33B USD — |
| NASDAQ Biotechnology Total Retu XNBI | 4633.82 USD — |
-1.19
|
— — | 4606.47 USD — | 4646.26 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 20585.06 USD — |
-0.58
|
— — | 20528.35 USD — | 20669.02 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 967.78 USD — |
-1.12
|
— — | 964.91 USD — | 969.79 USD — | — - | — — |
- {{ link.label }} {{link}}